Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
152 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Amyloidosis - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Amyloidosis - Pipeline Review, H2 2016', provides an overview of the Amyloidosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Amyloidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Amyloidosis - The report reviews pipeline therapeutics for Amyloidosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Amyloidosis therapeutics and enlists all their major and minor projects - The report assesses Amyloidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Amyloidosis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Amyloidosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Amyloidosis Overview 10 Therapeutics Development 11 Pipeline Products for Amyloidosis - Overview 11 Pipeline Products for Amyloidosis - Comparative Analysis 12 Amyloidosis - Therapeutics under Development by Companies 13 Amyloidosis - Therapeutics under Investigation by Universities/Institutes 15 Amyloidosis - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Amyloidosis - Products under Development by Companies 19 Amyloidosis - Products under Investigation by Universities/Institutes 21 Amyloidosis - Companies Involved in Therapeutics Development 22 Alnylam Pharmaceuticals, Inc. 22 Amgen Inc. 23 Arcturus Therapeutics, Inc. 24 BELLUS Health Inc. 25 Bsim2 26 Celgene Corporation 27 GlaxoSmithKline Plc 28 Ionis Pharmaceuticals, Inc. 29 Johnson & Johnson 30 Neurimmune Holding AG 31 NeuroPhage Pharmaceuticals, Inc. 32 Oncopeptides AB 33 Pfizer Inc. 34 Prothena Corporation Plc 35 Regeneron Pharmaceuticals, Inc. 36 SOM Innovation Biotech SL 37 Takeda Pharmaceutical Company Limited 38 Amyloidosis - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Combination Products 40 Assessment by Target 41 Assessment by Mechanism of Action 43 Assessment by Route of Administration 45 Assessment by Molecule Type 47 Drug Profiles 49 ALN-ANG - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 ALN-TTRsc02 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 carfilzomib - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 CLR-01 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 daratumumab - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 doxycycline hyclate - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 EDE-1307 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 GSK-2315698 + GSK-2398852 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 GSK-3039294 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 inotersen sodium - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 ixazomib citrate - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 LUNAR-TTR - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 Melflufen - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 Monoclonal Antibody for Amyloidosis - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 NEOD-001 - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 NI-301 - Drug Profile 103 Product Description 103 Mechanism Of Action 103 R&D Progress 103 NPT-005 - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 Oligonucleotides to Inhibit Transthyretin for Amyloidosis - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 patisiran - Drug Profile 106 Product Description 106 Mechanism Of Action 106 R&D Progress 106 pomalidomide - Drug Profile 113 Product Description 113 Mechanism Of Action 113 R&D Progress 113 PRX-004 - Drug Profile 120 Product Description 120 Mechanism Of Action 120 R&D Progress 120 revusiran - Drug Profile 121 Product Description 121 Mechanism Of Action 121 R&D Progress 121 Small Molecules for AL Amyloidosis - Drug Profile 126 Product Description 126 Mechanism Of Action 126 R&D Progress 126 Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile 127 Product Description 127 Mechanism Of Action 127 R&D Progress 127 Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Drug Profile 128 Product Description 128 Mechanism Of Action 128 R&D Progress 128 Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile 129 Product Description 129 Mechanism Of Action 129 R&D Progress 129 tafamidis meglumine - Drug Profile 130 Product Description 130 Mechanism Of Action 130 R&D Progress 130 tolcapone - Drug Profile 133 Product Description 133 Mechanism Of Action 133 R&D Progress 133 Amyloidosis - Dormant Projects 135 Amyloidosis - Product Development Milestones 136 Featured News & Press Releases 136 Jul 07, 2016: Ionis Pharmaceuticals Reports Positive Clinical Data on IONIS-TTR Rx at the XV International Symposium on Amyloidosis 136 Jul 05, 2016: Prothena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating Improvements in Three Organ Systems in Previously-Treated Patients with AL Amyloidosis 137 Jul 01, 2016: Alnylam Reports New Results on patisiran at the XV International Symposium on Amyloidosis 140 Jul 01, 2016: Alnylam To Present New Results on Revusiran at the XV International Symposium on Amyloidosis 142 Jun 27, 2016: Alnylam to Report New Patisiran Results at the XV International Symposium on Amyloidosis 144 Jun 27, 2016: Alnylam to Present New Revusiran Results at the XV International Symposium on Amyloidosis 144 Jun 21, 2016: Prothena to Present at 15th International Symposium on Amyloidosis Showcasing Broad Commitment to Advancing New Therapies for Systemic Amyloidoses 145 Jun 09, 2016: Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis 147 May 26, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program 148 May 23, 2016: Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at International Symposium on Amyloidosis 148 Apr 20, 2016: Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN) 149 Apr 07, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTRRX Program 150 Appendix 151 Methodology 151 Coverage 151 Secondary Research 151 Primary Research 151 Expert Panel Validation 151 Contact Us 151 Disclaimer 152
List of Tables
Number of Products under Development for Amyloidosis, H2 2016 11 Number of Products under Development for Amyloidosis - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Comparative Analysis by Late Stage Development, H2 2016 16 Comparative Analysis by Clinical Stage Development, H2 2016 17 Comparative Analysis by Early Stage Development, H2 2016 18 Products under Development by Companies, H2 2016 19 Products under Development by Companies, H2 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H2 2016 21 Amyloidosis - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 22 Amyloidosis - Pipeline by Amgen Inc., H2 2016 23 Amyloidosis - Pipeline by Arcturus Therapeutics, Inc., H2 2016 24 Amyloidosis - Pipeline by BELLUS Health Inc., H2 2016 25 Amyloidosis - Pipeline by Bsim2, H2 2016 26 Amyloidosis - Pipeline by Celgene Corporation, H2 2016 27 Amyloidosis - Pipeline by GlaxoSmithKline Plc, H2 2016 28 Amyloidosis - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016 29 Amyloidosis - Pipeline by Johnson & Johnson, H2 2016 30 Amyloidosis - Pipeline by Neurimmune Holding AG, H2 2016 31 Amyloidosis - Pipeline by NeuroPhage Pharmaceuticals, Inc., H2 2016 32 Amyloidosis - Pipeline by Oncopeptides AB, H2 2016 33 Amyloidosis - Pipeline by Pfizer Inc., H2 2016 34 Amyloidosis - Pipeline by Prothena Corporation Plc, H2 2016 35 Amyloidosis - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016 36 Amyloidosis - Pipeline by SOM Innovation Biotech SL, H2 2016 37 Amyloidosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 38 Assessment by Monotherapy Products, H2 2016 39 Assessment by Combination Products, H2 2016 40 Number of Products by Stage and Target, H2 2016 42 Number of Products by Stage and Mechanism of Action, H2 2016 44 Number of Products by Stage and Route of Administration, H2 2016 46 Number of Products by Stage and Molecule Type, H2 2016 48 Amyloidosis - Dormant Projects, H2 2016 135
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
